Abstract
A simple, accurate and sensitive kinetic method has been developed for the determination of three cardiovascular drugs: Betaxolol, Clopidogrel, and Imidapril in pharmaceutical formulations. The method is based on the alkaline oxidation of the selected drugs with potassium manganate(VII) at room temperature (25°C) to produce a bluish-green colored product. The reaction is followed spectrophotometrically by measuring the rate of change of absorbance at 610 nm as a function of time. The fixed-time (ΔA) method is adopted for constructing the calibration curves, which were found to be linear over the concentration ranges of 0.40-2.0 μg ml-1 Betaxolol, 1.0-10.0 μg ml-1 Clopidogrel, and 6.0-16.0 μg ml-1 Imidapril. The implemented fixed times were 15 min for Betaxolol and Clopidogrel and 10 min for Imidapril. The proposed method has been successfully applied to pharmaceutical formulations of each drug. The percentage relative error and the coefficient of variation were less than 0.6 and 1.2 respectively. The lower limits of quantitation (LOQ) were 9.75x10-7 M Betaxolol, 3.62x10-6 M Clopidogrel, and 4.22x10-6 M Imidapril. The determination of the investigated drugs by the fixed-concentration and the rate-constant methods is feasible with the regression equations obtained, but the fixed-time method proves to be more applicable.
Keywords: Betaxolol, Clopidogrel, Imidapril, Potassium manganate(VII), Kinetic spectrophotometry
Current Analytical Chemistry
Title: Kinetic Spectrophotometric Determination of Betaxolol, Clopidogrel and Imidapril in Pharmaceutical Preparations
Volume: 6 Issue: 3
Author(s): Fawzy A. El Yazbi, Mohamad E. Mahrous, Hassan H. Hammud, Ghassan M. Sonji and Nada M. Sonji
Affiliation:
Keywords: Betaxolol, Clopidogrel, Imidapril, Potassium manganate(VII), Kinetic spectrophotometry
Abstract: A simple, accurate and sensitive kinetic method has been developed for the determination of three cardiovascular drugs: Betaxolol, Clopidogrel, and Imidapril in pharmaceutical formulations. The method is based on the alkaline oxidation of the selected drugs with potassium manganate(VII) at room temperature (25°C) to produce a bluish-green colored product. The reaction is followed spectrophotometrically by measuring the rate of change of absorbance at 610 nm as a function of time. The fixed-time (ΔA) method is adopted for constructing the calibration curves, which were found to be linear over the concentration ranges of 0.40-2.0 μg ml-1 Betaxolol, 1.0-10.0 μg ml-1 Clopidogrel, and 6.0-16.0 μg ml-1 Imidapril. The implemented fixed times were 15 min for Betaxolol and Clopidogrel and 10 min for Imidapril. The proposed method has been successfully applied to pharmaceutical formulations of each drug. The percentage relative error and the coefficient of variation were less than 0.6 and 1.2 respectively. The lower limits of quantitation (LOQ) were 9.75x10-7 M Betaxolol, 3.62x10-6 M Clopidogrel, and 4.22x10-6 M Imidapril. The determination of the investigated drugs by the fixed-concentration and the rate-constant methods is feasible with the regression equations obtained, but the fixed-time method proves to be more applicable.
Export Options
About this article
Cite this article as:
A. El Yazbi Fawzy, E. Mahrous Mohamad, H. Hammud Hassan, M. Sonji Ghassan and M. Sonji Nada, Kinetic Spectrophotometric Determination of Betaxolol, Clopidogrel and Imidapril in Pharmaceutical Preparations, Current Analytical Chemistry 2010; 6 (3) . https://dx.doi.org/10.2174/157341110791517007
DOI https://dx.doi.org/10.2174/157341110791517007 |
Print ISSN 1573-4110 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6727 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Effects of Hypertension, Diabetes Mellitus, Obesity and Other Factors on Kidney Haemodynamics
Current Vascular Pharmacology An Overview of Valuable Scientific Models for Diabetes Mellitus
Current Diabetes Reviews Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
Current Vascular Pharmacology Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Current Vascular Pharmacology Editorial (Thematic Issue: Renal Endothelial Dysfunction: Evolving Concepts And Perspectives)
Cardiovascular & Hematological Disorders-Drug Targets Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Lithium and Kidney, 60 Years Later
Current Drug Safety Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Therapeutic Potential of Caffeic Acid Phenethyl Ester (CAPE) in Diabetes
Current Medicinal Chemistry Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry